Groupama Asset Managment Sells 151,870 Shares of Abbott Laboratories (NYSE:ABT)

Groupama Asset Managment trimmed its position in Abbott Laboratories (NYSE:ABT - Free Report) by 66.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 76,578 shares of the healthcare product maker's stock after selling 151,870 shares during the quarter. Groupama Asset Managment's holdings in Abbott Laboratories were worth $8,638,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of ABT. Noble Wealth Management PBC acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at about $26,000. NewSquare Capital LLC grew its holdings in Abbott Laboratories by 78.4% in the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker's stock valued at $27,000 after buying an additional 105 shares during the last quarter. WealthTrak Capital Management LLC bought a new position in Abbott Laboratories in the 4th quarter worth approximately $28,000. Rialto Wealth Management LLC bought a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $29,000. Finally, Wingate Wealth Advisors Inc. acquired a new stake in shares of Abbott Laboratories in the fourth quarter worth $34,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the company's stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $128.50, for a total transaction of $3,054,573.50. Following the transaction, the executive vice president now owns 125,697 shares of the company's stock, valued at approximately $16,152,064.50. This represents a 15.90 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Eric Shroff sold 562 shares of Abbott Laboratories stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total value of $77,651.54. Following the completion of the sale, the senior vice president now directly owns 31,970 shares of the company's stock, valued at $4,417,294.90. This trade represents a 1.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 116,449 shares of company stock worth $15,463,316 in the last 90 days. Corporate insiders own 0.46% of the company's stock.

Remove Ads

Abbott Laboratories Price Performance

ABT stock traded down $7.17 during trading on Friday, hitting $124.46. 10,775,333 shares of the stock traded hands, compared to its average volume of 5,905,172. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. The stock has a market cap of $215.85 billion, a price-to-earnings ratio of 16.27, a P/E/G ratio of 2.52 and a beta of 0.80. Abbott Laboratories has a one year low of $99.71 and a one year high of $141.23. The company has a 50 day simple moving average of $131.18 and a 200 day simple moving average of $120.84.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 EPS for the quarter, hitting the consensus estimate of $1.34. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The business had revenue of $10.97 billion for the quarter, compared to the consensus estimate of $11.03 billion. During the same period in the previous year, the business earned $1.19 EPS. Abbott Laboratories's revenue was up 7.2% compared to the same quarter last year. Equities analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be issued a $0.59 dividend. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.90%. Abbott Laboratories's dividend payout ratio is 30.85%.

Wall Street Analyst Weigh In

Several equities analysts recently commented on ABT shares. Argus upgraded shares of Abbott Laboratories to a "strong-buy" rating in a research note on Tuesday, January 28th. Citigroup increased their target price on shares of Abbott Laboratories from $135.00 to $160.00 and gave the company a "buy" rating in a research note on Tuesday, March 4th. UBS Group boosted their price target on Abbott Laboratories from $146.00 to $148.00 and gave the company a "buy" rating in a research note on Thursday, January 23rd. StockNews.com downgraded Abbott Laboratories from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, February 12th. Finally, Evercore ISI boosted their price objective on Abbott Laboratories to $136.00 and gave the company a "buy" rating in a research report on Thursday, January 2nd. Four analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and an average price target of $137.94.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.